Median progression-free survival was 7.6 months with the combination versus 5.4 with chemotherapy; results were presented at ...
Murray brings more than three decades in financial technology, including leadership at FIS, and will deepen client ...
OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN ...
Divarasib also reduced progression-or-death risk by 42%; no new safety signals were observed. Results appeared in The New ...
At median 15-month follow-up, 16 of 18 patients remained recurrence-free. A rectal cohort is enrolling to assess whether ...
After 17.8 months of median follow-up, NovaBridge selected 8 mg/kg for development and reports FDA alignment on a global ...
Without chemotherapy, the olomorasib combo's median progression-free survival was not reached after 20.7 months' median ...
Response rates were 75% first-line and 67% second-line; 79 patients had received the combination by May 15, and global Phase ...
Among 30 evaluable patients, 90% had disease control after progression on immunotherapy plus chemotherapy; results will ...
The rig had 115 people aboard; 110 have been safely accounted for as search-and-rescue operations continue, with Borr working ...
No mineral resource has been verified; further review is expected to check mineral rights, geology, permits, infrastructure, refining access and financing.
Ownership, mineral rights, geology, permits, financing and deal terms still need review; Elektros says no acquisition or production timetable is guaranteed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results